Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
United Kingdom
Biotech
A year after Big Pharma’s pull-back from the UK, what’s changed?
A year on from Big Pharma's protest at U.K. drug pricing policy, Fierce reached out to the companies involved to see if they've softened their stance.
James Waldron
Sep 4, 2026 10:00am
AZ restarts £300M UK investment, but Merck not budging
Apr 29, 2026 10:01am
US, UK regulators bolster medical device collaboration
Apr 6, 2026 10:20am
Fierce Pharma
UK government agrees to pharma deal, ensuring tariff reprieve
Apr 2, 2026 3:34pm
CRO Sygnature Discovery plans to send 60 UK staffers packing
Jan 30, 2026 5:00pm
AstraZeneca: Building a transparent pipeline from the ground up
Oct 10, 2025 9:52am
